{
    "clinical_study": {
        "@rank": "99135", 
        "arm_group": [
            {
                "arm_group_label": "Omalizumab and Prednisone", 
                "arm_group_type": "Active Comparator", 
                "description": "Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone\nStandard clinical therapy with prednisone.\nDay 1-14: 60 mg/day 14 days (2 weeks)\nDay 15-28: 40 mg/day (2 weeks)\nDay 29-35: 30 mg/day (1 week)\nDay 36-42: 20 mg/day (1 week)\nDay 43-49: 10 mg/day (1 week)\nDay 50-56:  5 mg/day (1 week)\nSubjects will stop taking prednisone on day 57\nIf patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
            }, 
            {
                "arm_group_label": "Prednisone", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard clinical therapy with prednisone.\nDay 1-14: 60 mg/day 14 days (2 weeks)\nDay 15-28: 40 mg/day (2 weeks)\nDay 29-35: 30 mg/day (1 week)\nDay 36-42: 20 mg/day (1 week)\nDay 43-49: 10 mg/day (1 week)\nDay 50-56:  5 mg/day (1 week)\nSubjects will stop taking prednisone on day 57\nIf patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators goal is to evaluate the role of XOLAIR\u00ae in treatment of Acute\n      Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of\n      prednisone for treatment of drug-induced AIN. Currently there is no good treatment for\n      drug-induced AIN. Prednisone is the standard treatment but is associated with many\n      side-effects when used long-term and at high doses."
        }, 
        "brief_title": "Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Interstitial Nephritis", 
        "condition_browse": {
            "mesh_term": [
                "Nephritis", 
                "Nephritis, Interstitial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult subjects > 18 years old of both genders\n\n          2. Biopsy proven acute interstitial nephritis in the native kidneys without evidence of\n             ischemic or glomerular pathology in the biopsy\n\n          3. Normal baseline creatinine defined as estimated GFR \u2265 60 ml/min/SA based on MDRD\n             calculation within 1 year prior to renal biopsy\n\n          4. Serum creatinine elevation of > 0.3 mg/dL and/or doubling of serum creatinine\n             compared to most recent documented creatinine available (at least within the last\n             year)\n\n          5. No immunosuppressants in the last three months including prednisone\n\n          6. Women of childbearing potential not using the contraception method can be included as\n             this is a one time dosing and has no known long-term effects.\n\n        Exclusion Criteria:\n\n          1. Unwillingness to give consent\n\n          2. Patients who are Pregnant (positive serum pregnancy test for females) or breast\n             feeding\n\n          3. Documented history of an autoimmune disease\n\n          4. Inability or unwillingness to take prednisone for the prescribed duration and/or dose\n\n          5. Subjects suspected to have non-drug-induced AIN\n\n          6. Subjects not meeting the inclusion criteria\n\n          7. Subjects with contraindication to administration of omalizumab\n\n          8. Prior use of omalizumab\n\n          9. Severe hypersensitivity to omalizumab or any component of the product\n\n         10. Known elevated IgE level from other disease processes\n\n         11. Subjects taking (nonsteroidal antiinflammatory drug) NSAIDs chronically\n\n         12. Use of any other investigational agents in the last 30 days\n\n         13. Patients with severe medical condition(s) including metastatic cancer, terminal\n             congestive heart failure, severe ischemic heart disease or any other medical\n             condition in which life expectancy is less than 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893658", 
            "org_study_id": "12-006797"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omalizumab and Prednisone", 
                "intervention_name": "Omalizumab", 
                "intervention_type": "Drug", 
                "other_name": "Xolair"
            }, 
            {
                "arm_group_label": [
                    "Omalizumab and Prednisone", 
                    "Prednisone"
                ], 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug", 
                "other_name": "Prednisolone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prednisolone", 
                "Prednisone", 
                "Omalizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Interstitial Nephritis", 
            "Nephritis", 
            "Tubulointerstitial", 
            "Renal disease", 
            "Kidney"
        ], 
        "lastchanged_date": "February 22, 2014", 
        "location": {
            "contact": {
                "email": "ryan.joanne@mayo.edu", 
                "last_name": "Joanne D. Ryan", 
                "phone": "507-266-8668"
            }, 
            "contact_backup": {
                "email": "mieras.kathleen@mayo.edu", 
                "last_name": "Kathleen S. Mieras, CCRP", 
                "phone": "507-284-9187"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": [
                {
                    "last_name": "Ladan Zand, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kaiser Lim, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Vesna D. Garovic, M.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)", 
        "overall_contact": {
            "email": "ryan.joanne@mayo.edu", 
            "last_name": "Joanne D. Ryan", 
            "phone": "507-266-8668"
        }, 
        "overall_contact_backup": {
            "email": "mieras.kathleen@mayo.edu", 
            "last_name": "Kathleen S Mieras, CCRP", 
            "phone": "507-284-9187"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Vesna D. Garovic, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in serum creatinine", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to three months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893658"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Vesna D. Garovic, M.D.", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean individual percentage drop in serum creatinine relative to entry creatinine levels", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to 3 months"
            }, 
            {
                "measure": "Percentage of subjects returning to their usual baseline creatinine (+25%) or below", 
                "safety_issue": "No", 
                "time_frame": "baseline to 3 months"
            }, 
            {
                "description": "24 hours, 4 hours, and in 3 months after Xolair treatment", 
                "measure": "Reduction in Neutrophil gelatinase-associated lipocalcin.", 
                "safety_issue": "No", 
                "time_frame": "baseline to 3 months"
            }, 
            {
                "measure": "Percentage of subjects requiring renal replacement therapy", 
                "safety_issue": "No", 
                "time_frame": "baseline to 3 months"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}